1. India Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Navin Fluorine International Limited

Navin Fluorine International Limited

NAVINFLUOR.BO
Navin Fluorine International LimitedIN flagBombay Stock Exchange
7,695.50
INR
+345.80
- -
395.32BMarket Cap
Navin Fluorine International Limited
NAVINFLUOR.BO
(Bombay Stock Exchange)

Recent

price

7,695.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
87.98
147.76
112.38
99.22
120.74
138.99
150.92
184.67
199.87
211.46
237.31
292.36
416.76
413.19
473.82
652.59
514.47
Revenue per Share
14.62
44.58
8.89
13.47
11.17
17.08
27.91
36.5
30.17
82.6
52.03
53.12
75.7
54.57
58.2
130.67
71.5
Basic EPS, GAAP
4.74
15.2
11.36
11.24
-12.55
11.88
-17.17
24.49
5.78
9.89
28
-101.79
-165.72
3.53
0.81
79.62
- -
Free Cash Flow per Basic Share
3.36
3.9
17.04
3.47
3.75
4.42
7.01
7.11
12.36
14.44
7.97
10.94
10.95
14.99
12
13.39
- -
Dividend per Share
2
52.84
57.35
66.02
71.95
101.34
121.89
150.28
167.37
235.19
279.1
320.93
385.6
424.95
471.32
2.02
- -
Book Value per Share
69.16
90.57
96.15
107.13
114.47
131.32
152.66
181.72
199
267.55
312.24
354.54
422.86
462.45
510.33
763.55
- -
Tangible Book Value per Share
49
49
49
49
49
49
49
49
49
49
49
50
50
50
50
51
50
Basic Weighted Avg Shares
4,294
7,211
5,485
4,843
5,895
6,795
7,386
9,095
9,877
10,460
11,745
14,480
20,654
20,483
23,494
33,139
25,511
Sales/Revenue/Turnover
-46.61
34.53
13.21
9.53
9.07
14.29
17.6
19.88
19.6
22.16
22.59
21.32
23.65
14.83
17.63
28.14
20.08
Operating Margin (%)
138
188
208
218
201
225
299
398
275
370
442
479
626
962
1,194
1,492
1,280
Depreciation Expense
713
2,176
434
657
546
835
1,366
1,798
1,491
4,086
2,575
2,631
3,752
2,705
2,886
6,636
3,545
Net Income, GAAP
32.55
29.16
36.95
21.25
25.59
27.74
24.75
31.53
34.3
- -
30.96
23.57
24.34
19.38
24.07
24.01
24.06
Effective Tax Rate (%)
16.62
30.17
7.91
13.57
9.26
12.29
18.49
19.77
15.1
39.06
21.93
18.17
18.17
13.21
12.28
20.02
13.9
Profit Margin (%)
823
706
1,213
1,986
1,470
1,754
1,877
3,536
3,839
6,005
9,927
6,354
8,640
7,667
6,742
17,173
- -
Working Capital
277
11
1
2
275
218
111
42
- -
153
156
1,100
7,596
10,402
10,666
9,724
- -
LT Debt
3,384
4,840
5,111
5,646
6,006
7,304
8,352
9,835
10,724
14,122
16,339
18,442
21,850
23,827
26,262
39,746
- -
Total Equity
-39.98
37.34
7.79
5.98
6.2
9.7
11.85
13.06
11.88
- -
11.82
12.97
14.72
7.2
8.03
15.18
- -
Return on Invested Capital (%)
249.46
111.15
12.76
17.85
13.05
17.67
23.61
26.33
18.89
- -
19.96
16.97
17.67
10.58
9.55
29.62
28.98
Return on Capital (%)
718.76
162.58
16.13
21.83
16.2
19.72
25.02
26.9
19.03
41.05
20.24
17.71
21.44
13.47
12.99
56.54
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
4,001
- -
LT Borrowings
- -
10,534
- -
LT Finance Leases
- -
132
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
50
- -
Market Capitalization
160,979
208,663
238,737

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
15,888
- -
Cash, Cash Equivalents & STI
- -
4,954
- -
Accounts Receivable, Net
- -
5,824
- -
Inventories
- -
3,224
- -
Total Current Liabilities
- -
9,147
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
4,001
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.05%
20.39%
51.34%
Free Cash Flow
901.76%
1,865.55%
9,907.67%
Net Income, GAAP
36.87%
30.7%
129.94%
Sales/Revenue/Turnover
17.95%
24.17%
41.05%
Total Cash Common Dividend
17.61%
13.78%
14.32%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,912
4,718
5,001
5,835
20,483
2025
5,237
5,186
6,062
7,009
23,494
2026
7,254
8,924
9,377
- -
33,139

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12.41
12.22
15.74
- -
54.57
2025
10.33
11.86
16.86
19.15
58.2
2026
23.63
36.18
41.49
- -
130.67

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
14.99
2025
- -
- -
- -
- -
12
2026
- -
- -
- -
- -
13.39
Similar Companies
Hawkins, Inc. (HWKN)
Zhejiang Runtu Co., Ltd. (002440.SZ)
Israel Corporation Ltd (IRLCF)
Aofu Environmental Technology Co., Ltd. (688021.SS)
Chinyang Holdings Corp. (100250.KS)
Perimeter Solutions, S.A. (PRMFF)
Business
Navin Fluorine International Limited manufactures specialty fluorochemicals and operates in the fluorine chemistry sector; its core products and services include refrigeration gases such as R-22 and R32; inorganic fluorides including anhydrous hydrofluoric acid, diluted hydrofluoric acid, synthetic cryolite and boron trifluoride with adducts; specialty organofluorines for applications in pharmaceuticals, agrochemicals, aluminium smelting, metal processing, abrasives, glass, ceramics, oil and gas, stainless steel and electronics; and contract development and manufacturing organization services encompassing process research, custom synthesis, contract research and cGMP pilot-to-commercial scale production of fluorinated molecules. The company, founded in 1967 as part of the Padmanabh Mafatlal Group, maintains headquarters in Mumbai, India, with primary manufacturing facilities at Surat and Dahej in Gujarat and Dewas in Madhya Pradesh; it also operates an R&D center at the Navin Research Innovation Center in Surat, a subsidiary in the UK called Manchester Organics Limited for early discovery phase work and a US sales office in Bridgewater, New Jersey. Navin Fluorine serves domestic and international customers, exporting over 40% of its more than 60 fluorinated products to North America, Europe, the Middle East and Asia Pacific, targeting top-tier life sciences, crop protection, petrochemical and specialty chemical companies including several Fortune 500 firms. Recent developments include a strategic agreement with The Chemours Company announced in May 2025 to manufacture Opteon two-phase immersion cooling fluid for data centers and AI hardware, with production slated to begin in 2026 at its Surat facility marking entry into advanced materials; commercialization of the Surat R32(II) project in fiscal 2025 adding 45,000 tonnes per annum capacity; commencement of operations at a new fluoro specialty chemical facility in Dahej with peak revenue potential of Rs 600 crore annually; completion of the Rs 160 crore Phase 1 cGMP-4 facility in Dewas in September 2025, already running validation batches for a European partner to bolster CDMO capabilities for pharmaceutical clients with full commercialization targeted for Q3 fiscal 2026; a Rs 750 crore qualified institutions placement in July 2025 to strengthen capital base; and partnerships such as with Buss ChemTech AG for solar and electronic grade hydrofluoric acid along with plans to launch two new fluoro intermediates for global agrochemical partners in fiscal 2026.